Evicenter
P&T meetings

Imsidolimab

Generalized pustular psoriasis

Regulatory submission
BLA submitted December 2025
Last updated
85 sources

Product information and disease descriptionPlace of product in therapy

Approaches to treatment

21 evidence topics · 16 sources

Heterogeneity of treatment effect

No evidence found.

Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.